Abstract:The mechanistic target of rapamycin (mTOR) integrates growth factor signals with cellular nutrient and energy levels and coordinates cell growth, proliferation and survival. A regulatory network with multiple feedback loops has evolved to ensure the exquisite regulation of cell growth and division. Colorectal cancer is the most intensively studied cancer because of its high incidence and mortality rate. Multiple genetic alterations are involved in colorectal carcinogenesis, including oncogenic Ras activation, phosphatidylinositol 3-kinase pathway hyperactivation, p53 mutation, and dysregulation of wnt pathway. Many oncogenic pathways activate the mTOR pathway. mTOR has emerged as an effective target for colorectal cancer therapy. In vitro and preclinical studies targeting the mTOR pathway for colorectal cancer chemotherapy have provided promising perspectives. However, the overall objective response rates in major solid tumors achieved with single-agent rapalog therapy have been modest, especially in advanced metastatic colorectal cancer. Combination regimens of mTOR inhibitor with agents such as cytotoxic chemotherapy, inhibitors of vascular endothelial growth factor, epidermal growth factor receptor and Mitogen-activated protein kinase kinase (MEK) inhibitors are being intensively studied and appear to be promising. Further understanding of the molecular mechanism in mTOR signaling network is needed to develop optimized therapeutic regimens. In this paper, oncogenic gene alterations in colorectal cancer, as well as their interaction with the mTOR pathway, are systematically summarized. The most recent preclinical and clinical anticancer therapeutic endeavors are reviewed. New players in mTOR signaling pathway, such as non-steroidal anti-inflammatory drug and metformin with therapeutic potentials are also discussed here.

Mtor Signaling Pathway is a Target for the Treatment of Colorectal Cancer

Targeting Mtor Network in Colorectal Cancer Therapy

Significance of Mtor Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer

Combined Inhibition of Mek and Mtor Signaling Inhibits Initiation and Progression of Colorectal Cancer

Roles of mTOR and p-mTOR in gastrointestinal stromal tumors.

Combined Inhibition of Dnmt and Mtor Signaling Inhibits Formation and Growth of Colorectal Cancer

Targeting Mtor for Cancer Therapy

Mtor Signaling in Cancer and Mtor Inhibitors in Solid Tumor Targeting Therapy

Genomic Signature of MTOR Could Be an Immunogenicity Marker in Human Colorectal Cancer

Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway

mTOR Signaling is Involved in Indomethacin and Nimesulide Suppression of Colorectal Cancer Cell Growth via a COX-2 Independent Pathway

PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment

Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.

Expression of Phosphorylated Mammalian Target of Rapamycin in Colorectal Cancer and Its Significance

Mammalian Target of Rapamycin Pathway Inhibition Enhances the Effects of 5-Aza-dc on Suppressing Cell Proliferation in Human Gastric Cancer Cell Lines

Inhibition of JAK1, 2/STAT3 Signaling Induces Apoptosis, Cell Cycle Arrest, and Reduces Tumor Cell Invasion in Colorectal Cancer Cells

The Mechanistic Target of Rapamycin Complex 1 Pathway Contributes to the Anti-Tumor Effect of Granulocyte-Macrophage-Colony-Stimulating Factor-Producing T Helper Cells in Mouse Colorectal Cancer

Emerging Role of MicroRNAs in Mtor Signaling

Abstract 4597: RNA m1A methyltransferase TRMT61A induces MAPK/ERK signaling and is a therapeutic target in colorectal cancer

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy